• Mutation; HGNC; HGNC:11998; TP53; Simple; p.Pro278Ala (c.832C>G); ClinVar=VCV000376645; Zygosity=Unspecified (PubMed=12884349; PubMed=18006756).
  

PubMed=12884349; DOI=10.1002/hed.10274
Bradford C.R., Zhu S.-B., Ogawa H., Ogawa T., Ubell M., Narayan A., Johnson G., Wolf G.T., Fisher S.G., Carey T.E.
p53 mutation correlates with cisplatin sensitivity in head and neck squamous cell carcinoma lines.
Head Neck 25:654-661(2003)

PubMed=17312569; DOI=10.1002/hed.20478
Lin C.J., Grandis J.R., Carey T.E., Gollin S.M., Whiteside T.L., Koch W.M., Ferris R.L., Lai S.Y.
Head and neck squamous cell carcinoma cell lines: established models and rationale for selection.
Head Neck 29:163-188(2007)

PubMed=18006756; DOI=10.1158/1078-0432.CCR-07-1591
Friedman J., Nottingham L.K., Duggal P., Pernas F.G., Yan B., Yang X.-P., Chen Z., Van Waes C.
Deficient TP53 expression, function, and cisplatin sensitivity are restored by quinacrine in head and neck cancer.
Clin. Cancer Res. 13:6568-6578(2007)

PubMed=19760794; DOI=10.1002/hed.21198; PMCID=PMC3292176
Brenner J.C., Graham M.P., Kumar B., Saunders L.M., Kupfer R., Lyons R.H., Bradford C.R., Carey T.E.
Genotyping of 73 UM-SCC head and neck squamous cell carcinoma cell lines.
Head Neck 32:417-426(2010)

PubMed=31090975; DOI=10.1002/hed.25803; PMCID=PMC6692232
Mann J.E., Kulkarni A., Birkeland A.C., Kafelghazal J., Eisenberg J., Jewell B.M., Ludwig M.L., Spector M.E., Jiang H., Carey T.E., Brenner J.C.
The molecular landscape of the University of Michigan laryngeal squamous cell carcinoma cell line panel.
Head Neck 41:3114-3124(2019)